Debio 1455

The Debio 1455 program includes novel microbiome therapeutics for the treatment of gastrointestinal (GI) disorders. Currently in drug candidate identification stage, the program aims to identify effective treatment against inflammatory bowel disease (IBD) and other GI disorders. The program is focused on novel, narrow spectrum, microbiome remodelling agents targeting a combination of intestinal pathobiont bacterial species. Drug candidates will be evaluated for their effectiveness against specific disease-causing microorganisms while preserving the natural balance of the microbiota.